Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$120,000.00
Hodgkin Lymphoma Treatment Revolution: Advanced Drug Screening in a 3D-Biomimetic Tumour-Associated Macrophage-Integrated Model
FY 2024-25
Summary
(Supervisor: Dr. Molly Shoichet, University of Toronto) Hodgkin lymphoma (HL) is a rare type of cancer that affects the lymphatic system, a key part of our body's defence system. HL impacts thousands of Canadians each year. Understanding and improving treatments for HL is crucial because current therapies may not be effective for everyone. The progression of HL is influenced by the environment around the tumour, especially by certain immune cells called tumour-associated macrophages (TAMs). These cells can help the cancer grow and spread. Our research uses a specialized 3D gel-like material that can grow HL cells and TAMs to study their interactions. This gel closely mimics the real tumour environment and helps us observe how TAMs invade and affect tumours, which can reveal new ways to target these processes in treatment. We believe that using this 3D gel-like material to mimic how HL and TAMs interact in the body can help us discover many new drugs that could slow down or stop HL. Our goals are: (1) to test a wide range of drugs to find those that disrupt the interaction between HL and TAMs, (2) to understand how the most promising drugs work, and (3) to test these drugs further for their effectiveness and safety using cells taken directly from HL patients. This research represents a groundbreaking approach in drug discovery, offering the potential to find new treatments for HL and improve cancer therapies at large. By deepening our understanding of how tumours interact with their environment, we hope to improve outcomes for all cancer patients and their families.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
518306
Name
Chin Allysia A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Hodgkin Lymphoma Treatment Revolution: Advanced Drug Screening in a 3D-Biomimetic Tumour-Associated Macrophage-Integrated Model
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
3d Biomimetic Cancer-Immune Cell Co-Culture Hydrogel Model; 3d High-Throughput Drug Screening In Hodgkin Lymphoma; Dose-Response Curves/Drug Potency And Efficacy; Gene Set Enrichment Analysis For Mechanism Elucidation; Hodgkin Lymphoma Tumour Microenvironment; Hyaluronan And Gelatin-Based Biomaterials; Single Cell Rna Sequencing/Flow Cytometry/Viability Assays; Synthesis And Characterization Of Tunable 3d Hydrogels; Targeting Tumor-Associated Macrophages In Hodgkin Lymphoma; Translational Medicine In Cancer Immunology
Abstract
(Supervisor: Dr. Molly Shoichet, University of Toronto) Hodgkin lymphoma (HL) is a rare type of cancer that affects the lymphatic system, a key part of our body's defence system. HL impacts thousands of Canadians each year. Understanding and improving treatments for HL is crucial because current therapies may not be effective for everyone. The progression of HL is influenced by the environment around the tumour, especially by certain immune cells called tumour-associated macrophages (TAMs). These cells can help the cancer grow and spread. Our research uses a specialized 3D gel-like material that can grow HL cells and TAMs to study their interactions. This gel closely mimics the real tumour environment and helps us observe how TAMs invade and affect tumours, which can reveal new ways to target these processes in treatment. We believe that using this 3D gel-like material to mimic how HL and TAMs interact in the body can help us discover many new drugs that could slow down or stop HL. Our goals are: (1) to test a wide range of drugs to find those that disrupt the interaction between HL and TAMs, (2) to understand how the most promising drugs work, and (3) to test these drugs further for their effectiveness and safety using cells taken directly from HL patients. This research represents a groundbreaking approach in drug discovery, offering the potential to find new treatments for HL and improve cancer therapies at large. By deepening our understanding of how tumours interact with their environment, we hope to improve outcomes for all cancer patients and their families.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Chin, Allysia A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~